Timber Pharmaceuticals To Present Interim Analyses From Phase 3 ASCEND Study Of TMB-001 In Congenital Ichthyosis
Portfolio Pulse from Happy Mohamed
Timber Pharmaceuticals announced interim pharmacokinetic analyses from the Phase 3 ASCEND study, indicating minimal systemic absorption of isotretinoin in patients with congenital ichthyosis treated with TMB-001. The full results will be presented at the Society for Pediatric Dermatology's Annual Meeting.
June 20, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Timber Pharmaceuticals' Phase 3 ASCEND study shows promising interim results for TMB-001 in treating congenital ichthyosis, potentially leading to better safety and lower systemic toxicity.
The interim results indicate minimal systemic absorption of isotretinoin in patients treated with TMB-001, which could lead to better safety and lower systemic toxicity. This is positive news for Timber Pharmaceuticals as it may increase the chances of TMB-001's approval and commercial success.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100